OpGen

OpGen is a precision medicine company leveraging the power of molecular diagnostics and bioinformatics to help combat infectious diseases. Together with its subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen develops and commercializes molecular microbiology solutions to assist clinicians in delivering faster and actionable information about life-threatening infections, improving patient outcomes. Our innovative approaches in infectious disease diagnostics include highly multiplexed syndromic molecular tests, as well as next-generation sequencing combined with intelligent bioinformatics and artificial intelligence to address the global threat of antimicrobial resistance (AMR). By integrating these capabilities, we provide unique rapid molecular diagnostic products and services that guide antibiotic treatment decisions through the use of precision medicine, optimize the treatment of life-threatening resistant infections, improve antibiotic stewardship, significantly transform patient care, and reduce the spread of multidrug-resistant organisms (MDROs).